TheraCea Pharma wins the UACI Sponsored Launch Fueled by Spencer Fane LLP competition. We will continue to receive support in the UACI incubation program including resources, facilities, services and expert guidance to grow its business.

TheraCea was selected from the pool of applicants for its drive in pursuing an innovative solution that addresses a real-world challenge. TheraCea is unleashing the power of precision medicine by developing clinical diagnostic tools for faster and more accurate detection of cancer and neurological disorders, as well as for best-in-class therapy matching and rapid assessment of therapy efficacy.

The selection was based on TheraCea’s dedication to commercializing its innovation and pursuing a scalable business model. TheraCea has partnered with the National Science Foundation and the National Institutes of Health to move its technology from the chemistry bench to clinics. With more business support, the team has an even greater ability to make a difference both locally and globally.